Core Viewpoint - Chao Yan Co., Ltd. has shown a stable financial performance with a notable increase in revenue and net profit, while also experiencing changes in shareholder structure and trading activity [1][2][3]. Financial Performance - For the first half of 2025, Chao Yan Co., Ltd. achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15% [2]. - The net profit attributable to shareholders reached 68.45 million yuan, marking an 18.5% increase compared to the previous period [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 16.65% to 22,300, while the average circulating shares per person increased by 19.98% to 2,456 shares [2]. - The top circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder [3]. - Other notable new shareholders include Southern Zhongzheng 1000 ETF and Huaxia Zhongzheng 1000 ETF, indicating a shift in institutional holdings [3]. Trading Activity - On October 27, 2023, Chao Yan Co., Ltd. experienced a slight decline of 0.36% in stock price, with a trading volume of 50.21 million yuan [1]. - The financing buy-in amount for the day was 7.87 million yuan, with a net buy of 5.14 million yuan after repayments [1]. - The total margin trading balance reached 97.31 million yuan, with financing accounting for 6.68% of the circulating market value [1].

Core Viewpoint - Chao Yan Co., Ltd. has shown a slight increase in stock price and trading volume, with notable financing activities indicating investor interest and potential growth in the medical imaging and industrial non-destructive testing sectors [1][2]. Financing and Trading Activity - On October 24, Chao Yan Co., Ltd. experienced a stock price increase of 0.52% with a trading volume of 56.81 million yuan. The financing buy-in amounted to 3.27 million yuan, while the financing repayment was 4.04 million yuan, resulting in a net financing outflow of 0.77 million yuan. The total financing and securities balance reached 92.15 million yuan [1]. - The current financing balance is 91.98 million yuan, representing 6.30% of the circulating market value. In terms of securities lending, 1,200 shares were repaid with no shares sold on October 24, leading to a remaining securities lending balance of 6,800 shares valued at 170,100 yuan [1]. Company Performance - As of June 30, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period. The average circulating shares per person increased by 19.98% to 2,456 shares. For the first half of 2025, the company reported a revenue of 184 million yuan, reflecting a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [2]. - Since its A-share listing, Chao Yan Co., Ltd. has distributed a total of 43.69 million yuan in dividends [3]. Shareholder Composition - As of June 30, 2025, the largest shareholder among the top ten circulating shareholders is Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder. The second-largest is Southern Zhongzheng 1000 ETF with 514,500 shares, also a new shareholder. Hong Kong Central Clearing Limited is the fourth-largest shareholder with 470,000 shares, having increased its holdings by 21,600 shares compared to the previous period [3].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is experiencing growth in the pet economy and medical device sectors, benefiting from the depreciation of the RMB and its recent listing as a new stock under the registration system [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [3][7]. - The company was established on November 15, 1982, and was listed on January 22, 2025 [7]. - The main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to the parent company of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company had a shareholder count of 22,300, a decrease of 16.65% from the previous period, with an average of 2,456 circulating shares per person, an increase of 19.98% [8]. Market Activity - On October 23, the company's stock rose by 2.26%, with a trading volume of 64.68 million yuan and a turnover rate of 4.50%, bringing the total market capitalization to 10.657 billion yuan [1]. - The stock has seen a net inflow of 3.62 million yuan from major investors today, accounting for 0.06% of the total, with the industry ranking at 9 out of 131 [4][5]. Product and Innovation - The company showcased its innovative veterinary medical imaging products at the 97th WVC annual conference, engaging with industry experts on the development of animal healthcare [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices that utilizes 5G networks for remote image transmission and interaction, enhancing the capabilities of portable devices [2][3].

Core Insights - In 2025, a total of 81 companies successfully went public on the A-share market, raising a total of 78.464 billion yuan, with 5.745 billion yuan allocated for intermediary fees, accounting for 7.32% of the total fundraising [1][3] Summary by Category Overall Market Performance - The average fundraising amount per company was 969 million yuan, with an average intermediary fee of 70.925 million yuan, resulting in an average intermediary fee percentage of 11.40% [3] - The highest fundraising amount recorded was 18.171 billion yuan, with the highest intermediary fee reaching 212.132 million yuan, which accounted for 20.94% of the total fundraising [3] Intermediary Fees by Market Segment - **ChiNext**: - Total fundraising: 709 million yuan - Total intermediary fees: 68.502 million yuan - Intermediary fee percentage: 11.56% [5] - **STAR Market**: - Total fundraising: 1.015 billion yuan - Total intermediary fees: 94.409 million yuan - Intermediary fee percentage: 12.13% [5] - **Main Board**: - Total fundraising: 1.643 billion yuan - Total intermediary fees: 90.072 million yuan - Intermediary fee percentage: 10.43% [5] - **Beijing Stock Exchange**: - Total fundraising: 320 million yuan - Total intermediary fees: 33.597 million yuan - Intermediary fee percentage: 12.34% [5] Notable Companies and Their Fees - **ChiNext**: - Highest intermediary fee: Han Shuo Technology (301275.SZ) with 132.488 million yuan, accounting for 11.41% of its 1.162 billion yuan fundraising [6] - Lowest intermediary fee: Chao Yan Co. (301602.SZ) with 41.064 million yuan, accounting for 9.54% of its 430 million yuan fundraising [6] - **STAR Market**: - Highest intermediary fee: Ying Shi Innovation (688775.SH) with 184.414 million yuan, accounting for 9.52% of its 1.938 billion yuan fundraising [7] - Lowest intermediary fee: Sai Fen Technology (688758.SH) with 45.213 million yuan, accounting for 20.94% of its 216 million yuan fundraising [7] - **Main Board**: - Highest intermediary fee: Huaneng New Energy (600930.SH) with 212.132 million yuan, accounting for 1.17% of its 18.171 billion yuan fundraising [8] - Lowest intermediary fee: Jiangnan New Materials (603124.SH) with 47.598 million yuan, accounting for 12.39% of its 384 million yuan fundraising [8] - **Beijing Stock Exchange**: - Highest intermediary fee: Kai Fa Technology (920029.BJ) with 59.725 million yuan, accounting for 5.11% of its 1.169 billion yuan fundraising [9] - Lowest intermediary fee: Hong Hai Technology (920108.BJ) with 18.426 million yuan, accounting for 14.38% of its 128 million yuan fundraising [9]

Core Viewpoint - Chao Yan Co., Ltd. has shown a slight decline in stock price and trading volume, with notable financing activities indicating investor sentiment and market dynamics [1][2]. Financing and Trading Activity - On October 22, Chao Yan Co., Ltd. experienced a stock price drop of 0.16% with a trading volume of 32.10 million yuan. The financing buy-in amounted to 2.52 million yuan, while financing repayment was 2.54 million yuan, resulting in a net financing outflow of 0.018 million yuan. The total financing and securities lending balance reached 95.12 million yuan [1]. - The current financing balance stands at 94.95 million yuan, representing 6.69% of the circulating market value. In terms of securities lending, 1,500 shares were repaid, and 600 shares were sold, with a selling amount of 14,600 yuan based on the closing price [1]. Company Overview - Chao Yan Co., Ltd., established on November 15, 1982, is located in Shantou, Guangdong Province. The company specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, recognized as a national key high-tech enterprise. The revenue composition includes 71.16% from medical ultrasound, 17.30% from industrial ultrasound, 5.72% from accessories, 4.56% from X-ray, and 1.26% from other sources [1]. Financial Performance - For the first half of 2025, Chao Yan Co., Ltd. reported a revenue of 184 million yuan, reflecting a year-on-year growth of 15%. The net profit attributable to shareholders reached 68.45 million yuan, marking an 18.5% increase compared to the previous period [2]. Shareholder and Institutional Holdings - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period. The average number of circulating shares per shareholder increased by 19.98% to 2,456 shares [2]. - The top ten circulating shareholders include new entrants such as Huabao Zhongzheng Medical ETF and Southern Zhongzheng 1000 ETF, with significant holdings of 1.91 million shares and 514,500 shares, respectively. Hong Kong Central Clearing Limited is the fourth-largest shareholder, increasing its holdings by 21,600 shares [3].

Core Insights - As of October 17, 2025, a total of 81 new IPOs have been launched, raising a total of 78.464 billion yuan, with 5.745 billion yuan allocated for intermediary fees, indicating that 7.32% of the raised funds are absorbed by intermediaries [1][2] Intermediary Fees Overview - The total intermediary fees for IPOs range from a minimum of 18.426 million yuan to a maximum of 212 million yuan, with the fee percentage varying from 1.17% to 20.94% [2] - The highest underwriting and sponsorship fee reached 17.6 million yuan, while audit and legal fees also increased with the raised funds [2] Average Intermediary Fees by Board - **ChiNext Board**: Average total intermediary fees are 68.502 million yuan, accounting for 11.56% of the raised funds; underwriting fees average 45.362 million yuan, audit fees 15.421 million yuan, and legal fees 7.721 million yuan [3] - **Sci-Tech Innovation Board**: Average total intermediary fees are 94.409 million yuan, accounting for 12.13% of the raised funds; underwriting fees average 68.962 million yuan, audit fees 17.148 million yuan, and legal fees 8.298 million yuan [3] - **Main Board**: Average total intermediary fees are 90.072 million yuan, accounting for 10.43% of the raised funds; underwriting fees average 63.683 million yuan, audit fees 18.001 million yuan, and legal fees 8.388 million yuan [3] - **North Exchange**: Average total intermediary fees are 33.597 million yuan, accounting for 12.34% of the raised funds; underwriting fees average 23.286 million yuan, audit fees 6.54 million yuan, and legal fees 3.771 million yuan [3] Detailed Intermediary Fees by Board - **ChiNext Board**: The highest intermediary fee is 132.488 million yuan by Hanshuo Technology, while the lowest is 41.064 million yuan by Chaoyan Co. [3] - **Sci-Tech Innovation Board**: The highest intermediary fee is 184.414 million yuan by Yingshi Innovation, while the lowest is 45.213 million yuan by Saifen Technology [3] - **Main Board**: The highest intermediary fee is 212.132 million yuan by Huadian New Energy, while the lowest is 47.598 million yuan by Jiangnan New Materials [3] - **North Exchange**: The highest intermediary fee is 59.725 million yuan by Kaifa Technology, while the lowest is 18.426 million yuan by Honghai Technology [3]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is a national key high-tech enterprise focusing on medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company had a shareholder count of 22,300, a decrease of 16.65% from the previous period, while the average circulating shares per person increased by 19.98% to 2,456 shares [8]. Market Position and Trends - The company participated in the 97th WVC annual meeting, showcasing innovations in veterinary medical imaging for pets, horses, and livestock, and engaging with industry experts [2]. - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [3]. Shareholder Structure - As of June 30, 2025, the top circulating shareholders include Huabao Zhongzheng Medical ETF, Southern Zhongzheng 1000 ETF, and Hong Kong Central Clearing Limited, with several new institutional shareholders entering [9].

Core Viewpoint - On October 17, Chao Yan Co., Ltd. experienced a decline of 2.07% in stock price, with a trading volume of 44.8858 million yuan, indicating a negative market sentiment towards the company [1] Financing Summary - On October 17, Chao Yan Co., Ltd. had a financing buy-in amount of 3.2515 million yuan and a financing repayment of 3.9078 million yuan, resulting in a net financing outflow of 656,300 yuan [1] - As of October 17, the total financing and securities lending balance for Chao Yan Co., Ltd. was 98.2781 million yuan, with the current financing balance at 98.0541 million yuan, accounting for 6.98% of the circulating market value [1] - In terms of securities lending, there were no shares repaid on October 17, with 100 shares sold short, amounting to 2,409 yuan at the closing price, and a remaining short position of 9,300 shares valued at 224,000 yuan [1] Company Overview - Chao Yan Co., Ltd., established on November 15, 1982, is located at 77 Jinsasha Road, Shantou City, Guangdong Province, and is recognized as a national key high-tech enterprise specializing in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [1] - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other supplementary sources (1.26%) [1] Financial Performance - As of June 30, Chao Yan Co., Ltd. had 22,300 shareholders, a decrease of 16.65% from the previous period, with an average of 2,456 circulating shares per person, an increase of 19.98% [2] - For the first half of 2025, the company achieved an operating income of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.4455 million yuan, up 18.50% year-on-year [2] - Since its A-share listing, Chao Yan Co., Ltd. has distributed a total of 43.6896 million yuan in dividends [2] Institutional Holdings - As of June 30, 2025, the largest circulating shareholder of Chao Yan Co., Ltd. was Huabao Zhongzheng Medical ETF (512170), holding 1.9127 million shares as a new shareholder [2] - The second largest circulating shareholder was Southern Zhongzheng 1000 ETF (512100), with 514,500 shares, also a new shareholder [2] - Other notable shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 21,600 shares, and Huaxia Zhongzheng 1000 ETF (159845), which is a new shareholder holding 304,800 shares [2]

Core Viewpoint - Chao Yan Co., Ltd. has shown a positive performance in stock trading and financial results, indicating growth potential in the medical imaging and industrial non-destructive testing equipment sectors [1][2]. Financial Performance - As of June 30, 2025, Chao Yan Co., Ltd. achieved a revenue of 184 million yuan, representing a year-on-year growth of 15% [2]. - The net profit attributable to shareholders for the same period was approximately 68.45 million yuan, reflecting an 18.5% increase compared to the previous year [2]. Stock Trading Activity - On October 14, 2023, Chao Yan Co., Ltd. saw a stock price increase of 2.24%, with a trading volume of approximately 92.23 million yuan [1]. - The financing buy-in amount for the same day was 6.48 million yuan, while the financing repayment was 6.92 million yuan, resulting in a net financing buy-in of -0.43 million yuan [1]. - The total financing and securities balance as of October 14, 2023, was approximately 95.63 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period [2]. - The average number of circulating shares per shareholder increased by 19.98% to 2,456 shares [2]. Dividend Distribution - Chao Yan Co., Ltd. has distributed a total of 43.69 million yuan in dividends since its A-share listing [3]. Institutional Holdings - As of June 30, 2025, the largest circulating shareholder was Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder [3]. - Other notable institutional shareholders include Southern Zhongzheng 1000 ETF and Hong Kong Central Clearing Limited, with significant shareholdings and increases [3].

Core Insights - The stock of Chao Yan Co., Ltd. experienced a decline of 1.60% on October 13, with a trading volume of 51.83 million yuan [1] - The company reported a financing net buy of -67,400 yuan on the same day, with a total financing and securities balance of 96.02 million yuan [1] Financing and Trading Data - On October 13, Chao Yan Co., Ltd. had a financing buy amount of 5.56 million yuan and a financing repayment of 5.62 million yuan [1] - The current financing balance is 95.85 million yuan, accounting for 6.68% of the circulating market value [1] - The company had no shares repaid in the securities lending segment, with 3,100 shares sold, amounting to 76,200 yuan at the closing price [1] Company Overview - Chao Yan Co., Ltd. is located in Shantou, Guangdong Province, and was established on November 15, 1982, with a listing date set for January 22, 2025 [1] - The company specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, recognized as a national key high-tech enterprise [1] - The revenue composition includes 71.16% from medical ultrasound, 17.30% from industrial ultrasound, 5.72% from accessories, 4.56% from X-ray, and 1.26% from other sources [1] Financial Performance - As of June 30, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period [2] - The average number of circulating shares per person increased by 19.98% to 2,456 shares [2] - For the first half of 2025, the company achieved a revenue of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [2] Dividend and Shareholding Structure - Chao Yan Co., Ltd. has distributed a total of 43.69 million yuan in dividends since its A-share listing [3] - As of June 30, 2025, the largest circulating shareholder is Huabao CSI Medical ETF, holding 1.91 million shares as a new shareholder [3] - Other notable shareholders include Southern CSI 1000 ETF and Hong Kong Central Clearing Limited, with increases in their holdings compared to the previous period [3]